Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Heart and Blood Diseases

Wounds and Injuries

Neoplasm Metastasis

Hematoma, Subdural

Neoplastic Processes

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Bevacizumab

Erlotinib Hydrochloride

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Patients will receive bevacizumab 10 mg/kg IV over 30-90 minutes every 2 weeks until disease progression or unacceptable toxicity.

bevacizumab

Patients will receive elrotinib 150 mg orally once a day continuously until disease progression or unacceptable toxicity.

erlotinib

Inkeun Park, M.D, Ph.D

Hye-won Ryu

Beo-Deul Kang

Jee Hyun Kim

Jung Hoon Kang

Joo-Hwan Park

Ju Won Kim

Min-Kyu Jung

Inkeun Park

Se-Jun Park

Hyeon-Su Im

A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle

The BRISK study will recruit patients with locally advanced or metastatic solid tumor harboring the genomic alterations in Krebs cycle (e.g. fumarate hydratase, isocitrate dehydrogenase, succinate dehydrogenase) who had disease progression on standard systemic treatment and/or has no standard treatment option, and investigate the efficacy and safety of bevacizumab plus erlotinib.

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

A Phase II Clinical Trial of Bevacizumab Plus eRlotinIb in patientS With Advanced Cancer Having Genetic Alterations in Krebs Cycle (BRISK, KCSG AL22-16)

Defined as a proportion of complete response (CR) + partial response (PR) according to RECIST v1.1, the fraction with a response (CR+PR) will be reported separately by cohort, along with a 95% confidence interval

Assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, PFS will be determined using the Kaplan-Meier method, and the curves presented along with a 95% confidence interval on the median PFS

The Kaplan-Meier method will be used and the curves presented along with a 95% confidence interval on the median OS

Severity of adverse events will be graded by NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) v5.0

Korean Cancer Study Group

Boryung Pharmaceutical Co., Ltd

Asan Medical Center

Clinical Associate Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer	NCT05904457	Solid Tumors Advanced Solid ... Metastatic Canc...	bevacizumab erlotinib	19 Years -	Asan Medical Center
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer	NCT05904457	Solid Tumors Advanced Solid ... Metastatic Canc...	bevacizumab erlotinib	19 Years -	Asan Medical Center

Spots Global Cancer Trial Database for fh

Every month we try and update this database with for fh cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for fh

Every month we try and update this database with for fh cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for fh cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.